Osiris Therapeutics has made history. The Columbia, MD-based biotech has won the first approval of an off-the-shelf therapy made with stem cells, a major milestone for the field but one with unremarkable business implications for the developer.
It takes a considerable level of patience, but if you dig deep into Osiris Therapeutics's latest update on its mid-stage study of the adult stem cell therapy Prochymal for Type 1 diabetes, you'll
In a major setback, Osiris Therapeutics announced this morning that preliminary results indicate that its stem cell therapy Prochymal failed both of its late-stage clinical trials. One analyst
Shares of Osiris Therapeutics slid nearly 10 percent in after-hours trading after the developer announced that interim data on Prochymal--a cutting-edge adult stem cell therapy--failed to demonstrate
Osiris Therapeutics has ended enrollment in a late-stage trial of Prochymal for Crohn's disease, saying that it believes that a design flaw spurred an unexpected placebo response. And that placebo
Osiris Therapeutics says its final set of two-year results from a trial for Prochymal, its cutting-edge adult stem cell therapy, met its primary endpoint on safety. Prochymal demonstrated fewer